EUVIMEDEUVIMED entdecken
Open Access

CXCR4-Targeted Macrophage-Derived Biomimetic Hybrid Vesicle Nanoplatform for Enhanced Cancer Therapy through Codelivery of Manganese and Doxorubicin

Yeonwoo Jang iD, Young Seok Cho iD, April Kim, Xingwu Zhou iD, Yujin Kim iD, Ziye Wan, James J Moon iD, Hansoo Park iD

ACS Applied Materials & Interfaces · 10.04.2024 · 16 (14) · 17129-17144

DOI: 10.1021/acsami.3c18569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 27.03.2024. Verfasst von Yeonwoo Jang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Integrative Engineering, Chung-Ang University, Seoul 06974, Republic of Korea. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIDDK NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplasmsHumansAnimalsMiceFemaleManganeseBiomimeticsDoxorubicinMacrophagesImmunotherapyPeptidesTumor MicroenvironmentCell Line, TumorReceptors, CXCR4

Stichwörter der Autor:innen

biomimetic hybrid vesiclecancer immunotherapycombination therapymacrophage-membrane-derived vesiclemembrane engineeringmetalloimmunotherapy

Substanzen

ManganeseDoxorubicinPeptidesCXCR4 protein, humanReceptors, CXCR4

Autor:innen und Institutionen

  • School of Integrative Engineering, Chung-Ang University, Seoul 06974, Republic of Korea.
  • Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States.
  • Biointerfaces Institute, University of Michigan, Ann Arbor, Michigan 48109, United States.
  • Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States.

ORCID-Profile: Yeonwoo Jang, Young Seok Cho, Xingwu Zhou, Yujin Kim, James J Moon, Hansoo Park

Förderung

  • NCI NIH HHS
  • NIDDK NIH HHS
  • NIGMS NIH HHS
  • NIBIB NIH HHS
  • NIDCR NIH HHS
  • NIAID NIH HHS
  • National Cancer Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Jang, Y., Cho, Y. S., Kim, A., Zhou, X., Kim, Y., Wan, Z., Moon, J. J., & Park, H. (2024). CXCR4-Targeted Macrophage-Derived Biomimetic Hybrid Vesicle Nanoplatform for Enhanced Cancer Therapy through Codelivery of Manganese and Doxorubicin. ACS Applied Materials & Interfaces, 16(14), 17129-17144. https://doi.org/10.1021/acsami.3c18569

Vancouver

Jang Y, Cho YS, Kim A, Zhou X, Kim Y, Wan Z, et al. CXCR4-Targeted Macrophage-Derived Biomimetic Hybrid Vesicle Nanoplatform for Enhanced Cancer Therapy through Codelivery of Manganese and Doxorubicin. ACS Applied Materials & Interfaces. 2024;16(14):17129-17144. doi:10.1021/acsami.3c18569

BibTeX
@article{Jang2024,
  author = {Jang, Yeonwoo and Cho, Young Seok and Kim, April and Zhou, Xingwu and Kim, Yujin and Wan, Ziye and Moon, James J and Park, Hansoo},
  title = {CXCR4-Targeted Macrophage-Derived Biomimetic Hybrid Vesicle Nanoplatform for Enhanced Cancer Therapy through Codelivery of Manganese and Doxorubicin},
  journal = {ACS Applied Materials & Interfaces},
  year = {2024},
  volume = {16},
  number = {14},
  pages = {17129--17144},
  doi = {10.1021/acsami.3c18569}
}
Kostenlos starten →